Novel Treatment Options in Insomnia for Better Patient Outcomes: A Focus on Dual Orexin Receptor Antagonists
September 21, 2022
6:00 am - 8:00 am
Complimentary breakfast will be served beginning at 6:00 am.
Marriott Marquis, Washington, DC
Liberty Salons IJKL, Meeting Level 4
1.5 CME/CNE/AAPA/AANP/AAFP Credits
FACULTY
Craig Chepke, MD, FAPA
Medical Director, Excel Psychiatric Associates;
Huntersville, NC
Paul P. Doghramji, MD
Senior Family Physician, Collegeville Family Practice
Medical Director of Health Services, Ursinus College
Collegeville, PA
Vanessa Joy Walker
Advocate, Speaker, and Coach
President and Founder of Living After Crisis Inc.
PROVIDER STATEMENT
Provided by HMP Education, an HMP Global Company.
For questions regarding this educational activity, or to cancel your account, please call 609-371-1137 or email accreditation@hmpglobal.com.
INTENDED LEARNERS
This activity is designed for family medicine and primary care clinicians, including
physicians, nurse practitioners, physician assistants, nurses, and other members of the multidisciplinary
healthcare team.
LEARNING OBJECTIVES
After participating in this activity, learners should be better able to:
- Asses current evidence associated with the suboptimal diagnosis and treatment
of insomnia in family practice settings - Evaluate expert clinical recommendations and safety/efficacy data associated with
current and emerging pharmacologic treatment options for insomnia, including
dual orexin receptor antagonists - Implement appropriate treatment strategies for patients with insomnia, including
dual orexin receptor antagonists, based on symptoms and comorbidities
ACTIVITY OVERVIEW
To be eligible for credit, participants must complete the educational activity and complete the evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: September 21, 2022
Expiration Date: October 19, 2022
Estimated Time to Complete: 1.5 hour
There is no fee associated with this activity.
HARDWARE/SOFTWARE REQUIREMENTS
The evaluation is accessible after the activity via a PC or Mac computer with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications.
CONTINUING EDUCATION
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
HMP Education designates this internet live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP CREDIT
The AAFP has reviewed Novel Treatment Options in Insomnia for Better Patient Outcomes: A Focus on Dual Orexin Receptor Antagonists and deemed it acceptable for up to 1.50 Live AAFP Prescribed credits. Term of Approval is from 09/21/2022 to 09/21/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To claim AAFP Prescribed Credits for this activity, you need to self-report your participation:
- Online
- By phone: (800) 274-2237
- By mail:
- American Academy of Family Physicians
- Attn: AAFP Member Resource Center
- 11400 Tomahawk Creek Parkway
- Leawood, KS 66211
NURSES
This continuing nursing education live activity awards 1.5 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hour.
NURSE PRACTITIONERS
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
PHYSICIAN ASSISTANTS
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live activity is designated for 1.5 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.
DISCLAIMERS
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
All relevant financial relationships have been mitigated.
FACULTY
The faculty has reported the following:
Dr. Chepke: Speaker's Bureau—AbbVie, Acadia, Alkermes, Corium, Eisai, Genomind, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sunovion, Takeda, Teva; Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Karuna, Neurocrine, Noven, Otsuka, Takeda, Teva; Advisory Board (spouse)— Otsuka; Consultant—AbbVie, Acadia, Alkermes, BioXcel, Corium, Eisai, Genomind, Intra-Cellular, Janssen, Jazz, Karuna, Lundbeck, MedinCell, Neurocrine, Noven, Otsuka, Sunovion; Grant/Research Support— Acadia, Axsome, Biohaven, Harmony, Neurocrine, Teva
Dr. Doghramji: Speaker's Bureau—Abbvie, Eisai, Idorsia, Kowa
Ms. Walker has disclosed no relevant financial relationship with any ineligible company (commercial interest).
CLINICAL REVIEWER
William C. Torrey, MD
Interim Chair
Department of Psychiatry
Dartmouth-Hitchcock
Lebanon, NH
Dr. Torrey has disclosed no relevant financial relationship with any ineligible company (commercial interest).
PLANNING COMMITTEE
Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California
Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).
HMP Education planners and staff include Samantha Conforti, Randy Robbin, and Andrea Zimmerman.
No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
ADA STATEMENT
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
PRIVACY POLICY
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.
GRIEVANCE POLICY
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at accreditation@hmpglobal.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.
COMMERCIAL SUPPORT
Supported by an independent educational grant from Idorsia Pharmaceuticals US Inc.